1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. China Isotope & Radiation Corporation
  6. News
  7. Summary
    1763   CNE1000031F4

CHINA ISOTOPE & RADIATION CORPORATION

(1763)
  Report
Delayed Hong Kong Stock Exchange  -  05/20 04:08:13 am EDT
19.94 HKD   +3.00%
04/19China Isotope & Radiation Corporation Proposes Final Dividend for 2021, Payable Before 23 July 2022
CI
03/30China Isotope & Radiation Corporation Reports Earnings Results for the Full Year Ended December 31, 2021
CI
01/03China Isotope & Radiation Forming JV to Produce, Sell Isotope Products in China
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

China Isotope & Radiation Corporation Enters into Investment Agreement Regarding the Establishment of CNNC Qinshan Isotope Co., Ltd. with CNNC Nuclear Power Operation Management Company and Haiyan State-Owned Assets Investment Company

12/31/2021 | 05:10am EDT

On 31 December 2021, the China Isotope & Radiation Corporation entered into the Investment Agreement regarding the establishment of CNNC Qinshan Isotope Co. Ltd. with CNNC Nuclear Power Operation Management Company and Haiyan State-owned Assets Investment Company. As at the date of this announcement, CNNC, which directly and indirectly holds approximately 73.83% of the total issued share capital of the Company through Atomic Energy Institute, Nuclear Power Institute, CNNC Fund, 404 Company and B.Y. Investment, is the controlling shareholder of the Company. CNNC holds 64.11% equity interest in China National Nuclear Power Co., Ltd, which holds 100% equity interest in CNNC Nuclear Operation Management Company. Therefore, CNNC Nuclear Operation Management Company is a connected person of the Company under Chapter 14A of the Listing Rules. Therefore, the entering into the Investment Agreement and the transaction contemplated thereunder constitutes a connected transaction of the Company under Chapter 14A of the Listing Rules. On 31 December 2021, the Company entered into the Investment Agreement regarding the establishment of CNNC Qinshan Isotope Co. Ltd. with CNNC Nuclear Operation Management Company and Haiyan State-owned Assets Investment Company. Name of the Joint CNNC Qinshan Isotope Co. Ltd., the final name shall be Venture Company: the name approved by the registration authority.


© S&P Capital IQ 2021
All news about CHINA ISOTOPE & RADIATION CORPORATION
04/19China Isotope & Radiation Corporation Proposes Final Dividend for 2021, Payable Before ..
CI
03/30China Isotope & Radiation Corporation Reports Earnings Results for the Full Year Ended ..
CI
01/03China Isotope & Radiation Forming JV to Produce, Sell Isotope Products in China
MT
2021China Isotope & Radiation Corporation Enters into Investment Agreement Regarding the Es..
CI
2021China Isotope & Radiation Arm Delivers Lutetium Chloride Solution for R&D in China; Sha..
MT
2021CHINA ISOTOPE & RADIATION : Forms Health Service Joint Venture With German Radiopharmaceut..
MT
2021CHINA ISOTOPE & RADIATION : H1 Profit Soars 48.5%; Shares Slump 11%
MT
2021CHINA ISOTOPE & RADIATION : CIRC JV's Radiotherapy Products Bag 26 Licenses in China; Shar..
MT
2021CHINA ISOTOPE & RADIATION : Voluntary announcement
PU
2021CHINA ISOTOPE & RADIATION : Poll results of the annual general meeting and distribution of..
PU
More news
Financials
Sales 2022 5 830 M 871 M 871 M
Net income 2022 384 M 57,4 M 57,4 M
Net Debt 2022 - - -
P/E ratio 2022 14,2x
Yield 2022 -
Capitalization 5 439 M 813 M 813 M
Capi. / Sales 2022 0,93x
Capi. / Sales 2023 0,80x
Nbr of Employees 3 120
Free-Float 83,1%
Chart CHINA ISOTOPE & RADIATION CORPORATION
Duration : Period :
China Isotope & Radiation Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHINA ISOTOPE & RADIATION CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 17,00 CNY
Average target price 25,55 CNY
Spread / Average Target 50,3%
EPS Revisions
Managers and Directors
Suo Hui Wang General Manager & Executive Director
Yan Bin Meng Chairman
Qing Jun Zhang Chairman-Supervisory Board
Qing Liang Guo Independent Non-Executive Director
Yan Meng Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
CHINA ISOTOPE & RADIATION CORPORATION-12.00%789
JOHNSON & JOHNSON2.59%457 706
PFIZER, INC.-14.23%284 192
ABBVIE INC.12.05%268 106
ROCHE HOLDING AG-16.41%265 188
ELI LILLY AND COMPANY3.64%257 689